(Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. Knockout studies in mice suggested that this receptor promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. The knockout studies also suggested the roles of this receptor in CD4+ T cell response, as well as in T cell-dependent B cell proliferation and differentiation. [provided by RefSeq, Jul 2008].
TNFRSF4
Spezies: Human
Wirt: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
FACS
Aktuelle Publikationen für unsere TNFRSF4 Proteine
Upadhyaya, Lahdenranta, Hurov, Battula, Dods, Haines, Kleyman, Kristensson, Kublin, Lani, Ma, Mudd, Repash, Van Rietschoten, Stephen, You, Harrison, Chen, McDonnell, Brandish, Keen: "Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist." in: Journal for immunotherapy of cancer, Vol. 9, Issue 1, (2021) (PubMed).
Simons, Lim, Carter, Wagner, Wayham, Adler, Johnson: "Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR." in: mAbs, Vol. 12, Issue 1, pp. 1803646, (2020) (PubMed).
Fromm, de Silva, Johannes, Patel, Hornblower, Schreiber: "Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy." in: Journal for immunotherapy of cancer, Vol. 6, Issue 1, pp. 149, (2018) (PubMed).